Total Payments
$61,825
2024 Payments
$24,736
Companies
12
Transactions
67
Medicare Patients
7,940
Medicare Billing
$5.5M
Payment Breakdown by Category
Consulting$48,207 (78.0%)
Research$7,353 (11.9%)
Travel$3,754 (6.1%)
Food & Beverage$2,423 (3.9%)
Education$87.92 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $48,207 | 15 | 78.0% |
| Unspecified | $7,353 | 7 | 11.9% |
| Travel and Lodging | $3,754 | 12 | 6.1% |
| Food and Beverage | $2,423 | 32 | 3.9% |
| Education | $87.92 | 1 | 0.1% |
Payments by Type
General
$54,472
60 transactions
Research
$7,353
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $32,573 | 32 | $0 (2024) |
| Hoffmann-La Roche Limited | $7,407 | 3 | $0 (2024) |
| Genentech, Inc. | $7,295 | 9 | $0 (2023) |
| F. Hoffmann-La Roche AG | $6,905 | 6 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $5,007 | 5 | $0 (2024) |
| ABBVIE INC. | $1,416 | 6 | $0 (2024) |
| Dutch Ophthalmic, USA | $839.68 | 1 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $140.91 | 1 | $0 (2022) |
| Sun Pharmaceutical Industries Inc. | $113.80 | 1 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $87.92 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,736 | 24 | Genentech USA, Inc. ($8,846) |
| 2023 | $23,670 | 15 | Genentech USA, Inc. ($12,398) |
| 2022 | $11,370 | 12 | Genentech USA, Inc. ($10,995) |
| 2021 | $334.81 | 4 | Genentech USA, Inc. ($136.95) |
| 2019 | $145.13 | 2 | Genentech USA, Inc. ($133.73) |
| 2018 | $99.64 | 3 | Genentech, Inc. ($81.62) |
| 2017 | $1,469 | 7 | AbbVie, Inc. ($1,336) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2024 | Dutch Ophthalmic, USA | EVA, combined machine (Device), TISSUEBLUE | Travel and Lodging | In-kind items and services | $839.68 | General |
| Category: Ophthalmology | ||||||
| 10/21/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $142.50 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $480.00 | Research |
| Study: Clinical Impact of the Port Delivery System With Ranibizumab (PDS) in Retinal Diseases • Category: Ophthalmology | ||||||
| 09/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/13/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $105.22 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/01/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/18/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $42.31 | General |
| Category: EYE CARE | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,566.67 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $919.11 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 05/23/2024 | Hoffmann-La Roche Limited | — | Consulting Fee | Cash or cash equivalent | $686.57 | General |
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | — | In-kind items and services | $448.80 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: OPHTHALMOLOGY | ||||||
| 05/02/2024 | Hoffmann-La Roche Limited | — | Consulting Fee | Cash or cash equivalent | $3,360.00 | General |
| 04/20/2024 | Genentech USA, Inc. | Susvimo (Drug) | Consulting Fee | Cash or cash equivalent | $7,560.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/20/2024 | Genentech USA, Inc. | Susvimo (Drug) | Travel and Lodging | In-kind items and services | $424.50 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/20/2024 | Genentech USA, Inc. | Susvimo (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/20/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $255.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/20/2024 | Genentech USA, Inc. | Susvimo (Drug) | Travel and Lodging | In-kind items and services | $98.69 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $2,288.60 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,275.83 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $374.44 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 03/18/2024 | Hoffmann-La Roche Limited | — | Consulting Fee | Cash or cash equivalent | $3,360.00 | General |
| 03/15/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/15/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $7.43 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/08/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $133.95 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/06/2023 | Genentech, Inc. | Susvimo (Drug) | Consulting Fee | Cash or cash equivalent | $2,795.00 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | F. Hoffmann-La Roche AG | $6,425 | 5 |
| Clinical Impact of the Port Delivery System With Ranibizumab (PDS) in Retinal Diseases | F. Hoffmann-La Roche AG | $480.00 | 1 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $448.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,075 | 15,486 | $6.2M | $1.4M |
| 2022 | 15 | 2,028 | 6,746 | $5.2M | $1.3M |
| 2021 | 15 | 2,219 | 6,467 | $6.0M | $1.5M |
| 2020 | 14 | 1,618 | 5,343 | $5.2M | $1.3M |
Total Patients
7,940
Total Services
34,042
Medicare Billing
$5.5M
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 106 | 1,084 | $2.3M | $746,543 | 33.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 33 | 10,020 | $1.5M | $289,055 | 19.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 20 | 414 | $330,372 | $74,042 | 22.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 155 | 696 | $1.2M | $72,099 | 5.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 425 | 619 | $199,937 | $64,904 | 32.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 478 | 918 | $201,042 | $63,640 | 31.7% |
| 92134 | Imaging of retina | Office | 2023 | 661 | 1,524 | $405,384 | $46,003 | 11.3% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 12 | 22 | $109,714 | $5,991 | 5.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $20,480 | $4,549 | 22.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 28 | 29 | $13,456 | $2,941 | 21.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 21 | 21 | $6,930 | $1,668 | 24.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 84 | 85 | $11,475 | $1,651 | 14.4% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 14 | 16 | $11,894 | $685.08 | 5.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 119 | 1,172 | $2.4M | $838,788 | 34.4% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 23 | 581 | $463,638 | $128,879 | 27.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 152 | 648 | $1.1M | $67,767 | 6.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 411 | 895 | $196,005 | $65,812 | 33.6% |
| 92134 | Imaging of retina | Office | 2022 | 646 | 1,558 | $414,428 | $48,038 | 11.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 297 | 429 | $138,567 | $45,530 | 32.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 11 | 1,080 | $157,680 | $32,229 | 20.4% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 132 | 132 | $50,292 | $8,436 | 16.8% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2022 | 15 | 21 | $104,727 | $5,356 | 5.1% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 63 | 64 | $16,832 | $4,556 | 27.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 35 | 35 | $16,240 | $3,464 | 21.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $12,883 | $3,372 | 26.2% |
About Dr. Manjot Gill, MD
Dr. Manjot Gill, MD is a Ophthalmology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396776894.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manjot Gill, MD has received a total of $61,825 in payments from pharmaceutical and medical device companies, with $24,736 received in 2024. These payments were reported across 67 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($48,207).
As a Medicare-enrolled provider, Gill has provided services to 7,940 Medicare beneficiaries, totaling 34,042 services with total Medicare billing of $5.5M. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Chicago, IL
- Active Since 07/05/2006
- Last Updated 07/08/2007
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1396776894
Products in Payments
- Susvimo (Drug) $15,730
- Vabysmo (Drug) $12,488
- Lucentis (Biological) $11,366
- VABYSMO (Drug) $6,795
- EYLEA (Biological) $4,415
- EVA, combined machine (Device) $839.68
- EYLEA HD (Biological) $591.30
- SUSVIMO (Drug) $238.65
- ACTHAR (Biological) $140.91
- Cequa (Drug) $113.80
- EYLEA AFLIBERCEPT INJECTION (Biological) $87.92
- OZURDEX (Drug) $80.29
- Syfovre (Drug) $30.22
- Non-Covered Product (Drug) $17.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Chicago
Seenu Hariprasad
Ophthalmology — Payments: $2.4M
Ophthalmology $2.4M
Dr. Yannek Leiderman, M.d., Ph.d, M.D., PH.D
Ophthalmology — Payments: $512,224
Ophthalmology $512,224
Jennifer Lim, M.d, M.D
Ophthalmology — Payments: $253,265
Ophthalmology $253,265
Asim Farooq
Ophthalmology — Payments: $210,059
Ophthalmology $210,059
Dr. Dilraj Grewal, Md, MD
Ophthalmology — Payments: $188,040
Ophthalmology $188,040
Surendra Basti, Md, MD
Ophthalmology — Payments: $163,230
Ophthalmology $163,230